Atorvastatin associated with gamma glutamyl transpeptidase elevation in a hyperlipidemia patient
A case report and literature review
Yan Xu, MD, PhD, Yanqing Wu, MD, PhD

Abstract

Rationale: Atorvastatin is the most common drug used in therapy for cardiovascular diseases. The most common adverse side effects associated with statins are myopathy and hypertransaminasemia. Here, we report a rare case of gamma glutamyl transpeptidase (GGT) elevation induced by atorvastatin.

Patient concerns: A 47-year-old male was admitted to our hospital with dyslipidemia, he had been taking pitavastatin 2 mg/day for 2 months. The levels of total cholesterol (265.28 mg/dL) and low-density lipoprotein-cholesterol (LDL) (179.15 mg/dL) were also high.

Diagnosis: Blood lipid test showed mixed dyslipidemia.

Intervention: Atorvastatin 10 mg/day was given to the patient.

Outcomes: The patient came back to our hospital for blood tests after 4 weeks. Although no symptoms were detectable, the patient’s GGT level was markedly elevated (up to 6-fold over normal level) with less marked increases in alkaline phosphatase (ALP) and alanine aminotransferase (ALT). The serum GGT level returned to normal within 6 weeks of cessation of atorvastatin.

Lessons: This is a case of GGT elevation without hyperbilirubinemia, hypertransaminasemia, or serum creatine phosphokinase (CPK) abnormalities despite an atorvastatin regimen. This case highlights GGT elevation caused by atorvastatin, a rare but serious condition. Clinicians should be aware of these possible adverse effects and monitor liver function tests in patients on statin therapy.

Abbreviations: ADR = adverse drug reactions, AFP = alpha-fetoprotein, ALP = alkaline phosphatase, ALT = alanine aminotransferase, ANAs = anti-nuclear antibodies, ASMA = anti-smooth muscle antibody, AST = glutamic oxaloacetic transaminase, CPK = creatine phosphokinase, DILI = drug-induced liver injury, GGT = glutamyl transpeptidase, LDL = low-density lipoprotein-cholesterol, TBIL = total bilirubin.

Keywords: γ-glutamyl transpeptidase (GGT), atorvastatin

1. Introduction

Statins are the most common drugs used for therapy for hyperlipidemia, coronary artery disease, and other atherosclerotic diseases in clinical practice. Statins have been shown to reduce cardiovascular events significantly in high-risk patients with and without hyperlipidemia. However, despite the beneficial impact of the statins themselves, such adverse effects as myopathy, myalgia, cognitive impairment, and liver dysfunction have also been of great concern and have significant limitations that mitigate clinical applicability. Atorvastatin (RLipitor) is a member of the medication class known as statins. Like all statins, atorvastatin works by inhibiting hydroxymethylglutaryl-coenzyme A reductase.

To the best of our knowledge, there have been no reported cases of atorvastatin-induced γ-glutamyl transpeptidase (GGT) elevation in the absence of hyperbilirubinemia, hypertransaminasemia, and serum creatine phosphokinase (CPK) abnormalities. We present here a case whose serum GGT level elevation was caused by atorvastatin.

2. Case presentation

A 47-year-old male was admitted to our hospital with dyslipidemia. He had been receiving pitavastatin 2 mg/day for
2 months. The levels of total cholesterol (265.28 mg/dL) and low-density lipoprotein-cholesterol (LDL) (179.15 mg/dL) were also high. The blood liver function test was normal. His height was 170.0 cm, and his weight was 65.0 kg, so his body mass index was 24.1. He had a history of smoking and no significant medical history of other conditions. He had no history of blood transfusions or alcohol intake. According to 2019 ESC/EAS Guidelines for the management of dyslipidemias, the patient had mid-level risk.\textsuperscript{[7]} Atorvastatin 10 mg/day was given to the patient, and he came back to our hospital for blood tests after 4 weeks. The result found his serum GGT level was markedly elevated (407 U/L), upper limit of normal: 61 U/L). The levels of serum alkaline phosphatase (ALP) (178 U/L, upper limit of normal: 129 U/L) and alanine aminotransferase (ALT) (51 U/L, upper limit of normal: 41 U/L) were slightly elevated, but the levels of serum CPK, total bilirubin (TBIL), and glutamic oxaloacetic transaminase (AST) level were normal. The patient denied any recent antibiotic use or alcohol intake. He was admitted as a gastroenterology outpatient four days later. Upon examination, there were no abnormal clinical signs. The serum biochemical index was reexamined, GGT level was also markedly elevated (402 U/L), ALP level was mildly increased (162 U/L), and the levels of ALT, AST, CPK, TBIL, direct bilirubin (DBIL), and indirect bilirubin (IBIL) were normal. Abdominal color Doppler ultrasound and computed tomography were obtained, and the results showed hepatic cysts. The serum alpha-fetoprotein (AFP) level was also normal, and tests for viral markers associated with hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis E virus, anti-nuclear antibodies (ANAs), and anti-smooth muscle antibody (ASMA) were all negative. His abnormal hepatic function was diagnosed as atorvastatin-induced hepatic injury. Atorvastatin therapy was discontinued, and no other drugs were used to treat abnormal hepatic function. On day 21, the patient returned to the hospital and underwent blood tests. Results revealed serum GGT levels were significantly decreased (152 U/L), and the levels of ALT and ALP were normal. The GGT level was normal 3 weeks later (Fig. 1 GGT levels during atorvastatin therapy).

Causality assessment in adverse drug reactions is challenging in clinical settings. The Naranjo Adverse Drug Reactions Probability Scale is a simple and widely used method of assessing the clinical settings. The Naranjo Adverse Drug Reactions Probability Scale is a simple and widely used method of assessing the overall probability of an ADR in drug-induced hepatotoxicity.\textsuperscript{[12]} According to the Naranjo scale, the probability of ADR is classified as definite (score over 9), probable (score 5–8), possible (score 1–4), or doubtful (0 or lower). With Naranjo’s assessment scale, the whole process was entered into the ADR evaluation system, and eventually scored 6 points (Table 1). The probability of GGT elevation was classified as probable by atorvastatin.

### Table 1
Naranjo’s probability scale for assessing atorvastatin-associated GGT elevation.

| Related problem                                      | yes | no | unknown | Score | Score reason                                                                 |
|------------------------------------------------------|-----|----|---------|-------|-------------------------------------------------------------------------------|
| Previous reports on the reaction                     |     |    |         | 0     | There was no related report                                                   |
| Temporal illegibility in the onset of reaction       | 2   |    |         | 0     | GGT was increased after atorvastatin usage                                   |
| Improvement after drug withdrawal                    | 1   |    |         | 0     | Serum GGT level returned to normal after atorvastatin withdrawal             |
| Positive re-challenge                                |     |    |         | 0     | Atorvastatin was not use again                                                |
| Exclusion of alternative causes for the ADR          | 2   |    |         | 0     | Viral hepatitis, autoimmune hepatitis and other causes by GGT elevation were exclusion |
| Placebo response                                     |     |    |         | 0     | There was no placebo                                                          |
| Drug concentration and monitoring                    | 0   |    |         | 0     | Drug concentration was not tested                                             |
| Dose relationship                                    |     |    |         | 0     | The dosage of atorvastatin was not changed                                  |
| Previous exposure and cross reactivity               | 0   |    |         | 0     | No                                                                             |
| Presence of any objective evidence                   | 1   |    |         | 6     | Blood GGT level test was abnormalities                                         |

3. Discussion

Muscle symptoms and hypertransaminasemia are common side effects of atorvastatin. There have been no reported that GGT elevation associated with atorvastatin in the absence of hyperbilirubinemia, hypertransaminasemia, and CPK abnormalities. The liver function of this patient was normal when atorvastatin was initially used, and the level of GGT was significantly higher when atorvastatin was given for 4 weeks. The clinical pharmacist considered that the abnormally high GGT was associated with atorvastatin when viral hepatitis and autoimmune hepatitis were ruled out. This conclusion was also supported by Naranjo’s assessment scale.

Up to 3% of patients develop a mild increase in transaminase within first year of statin therapy, but clinically apparent drug-induced liver injury is rare, and these increases often occur without symptoms and resolve spontaneously despite continued statin therapy.\textsuperscript{[9–11]} The elevation in aminotransferases levels in the absence of elevated bilirubin is not clearly linked to clinically or pathologically relevant liver injury.\textsuperscript{[12]} In clinical practice, the biomarkers include ALT, TBIL, and ALP, which are the standard analytes used to indicate liver damage and liver dysfunction in drug-induced liver injury.\textsuperscript{[14,13]} According to European Association
for the Study of the Liver clinical practice guidelines, there are three patterns of drug-induced liver injury: hepatocellular (5-fold or higher rise in ALT alone or when the ratio of serum activity of ALT to ALP is 5 or more), cholestatic (2-fold or higher rise in ALP alone or when the ratio of serum activity of ALT to ALP is 2 or lower), and mixed (the ratio of the serum activity of ALT to ALP is between 2 and 5). The ratio of ALT to ALP was less than 2 in this patient, but the levels of ALT and ALP were only slightly higher than normal upper limits, and the GGT level showed an abnormal increase. This raised the question of whether these changes could be explained by cholestasis induced by atorvastatin.

GGT is a microsomal enzyme located in the bile canaliculi, heart, kidney, lungs, pancreas, and seminal vesicles. The expression of GGT is essential to maintaining cysteine levels in the body. It has been reported that GGT plays an important role in the hepatobiliary system. The serum level of GGT has been used as an indicator of hepatic dysfunction and biliary tract disease, although the pathophysiological role of GGT itself remains unclear. The level of increase in GGT also often indicates acute hepatocyte damage. It is considered a preclinical and clinical biomarker for hepatotoxicity and hepatic injury. Genetic polymorphisms in CYP 3A4 may raise the question of whether these changes could be explained by cholestasis induced by atorvastatin.

GGT is a microsomal enzyme located in the bile canaliculi, heart, kidney, lungs, pancreas, and seminal vesicles. The expression of GGT is essential to maintaining cysteine levels in the body. It has been reported that GGT plays an important role in the hepatobiliary system. The serum level of GGT has been used as an indicator of hepatic dysfunction and biliary tract disease, although the pathophysiological role of GGT itself remains unclear. The level of increase in GGT also often indicates acute hepatocyte damage. It is considered a preclinical and clinical biomarker for hepatotoxicity and hepatic injury. Genetic polymorphisms in CYP 3A4 may raise the question of whether these changes could be explained by cholestasis induced by atorvastatin.

A high serum level of GGT is associated with an increased risk of cancer in clinical trials, such as liver cancer and pancreatic cancer. Enzymatic activity is also increased by enzyme-inducing drugs. In the absence of other causes of liver disorder, such as antitubercular agents, antitumor drugs, and herbal remedies, enzymatic activity can be increased by enzyme-inducing drugs. Basic experiments have shown the serum concentration of GGT can also act as a marker of oxidative stress, the extent of endothelial injury, and endothelial repair activity. The clinical usability of serum GGT as a marker of the development of cardiovascular disease is here explored. Shimizu et al. found that GGT had an association with hypertension and atherosclerosis. Abdominal imaging did not show cancer, and coronary CT angiography showed only slight atherosclerosis in this patient. The serum GGT level decreased to normal when atorvastatin was terminated. Therefore, we considered the abnormally high GGT level associated with atorvastatin.

Atorvastatin is largely metabolized in the liver via CYP 3A4. Genetic polymorphisms in CYP 3A4 may reflect differences in drug reactions. Dujovne et al. found that atorvastatin had more pronounced activity in lowering serum lipoprotein than CYP 3A4. This, in turn, could influence the structure of cellular membranes, leading to greater leakage of cellular enzymes (such as ALT, AST, ALP, and GGT) and increased incidence of liver-function test abnormalities without direct hepatotoxicity. Pitavastatin is minimally metabolized through CYP 450 enzymes; this might be the reason why the liver-function test was normal in this patient after given pitavastatin 2 months.

4. Conclusion

Although the side effects of atorvastatin have been described thoroughly in the literature, atorvastatin continues to appear to cause GGT elevation, especially in the absence of hyperbilirubinemia, hypertransaminasemia, and CPK abnormalities. Hence, clinicians should be aware of these possible adverse effects and monitor liver function tests in patients on statin therapy.

Author contributions

Conceptualization: Yan Xu. Supervision: Yanqing Wu. Writing – original draft: Yan Xu. Writing – review editing: Yanqing Wu.

References

[1] Sirtori CR. The pharmacology of statins. Pharmacol Res 2014;88:3–11.
[2] Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular out- comes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011;378:1356–67.
[3] Seshasai SR, Kaptopte S, Thompson A, et al. Emerging Risk Factors CollaborationDiabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829–41.
[4] Bays H, Cohen DE, Chalasani N, et al. The National Lipid Association’s Statin Task Force: An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol 2014;8(suppl. 3):S47–57.
[5] Villani R, Navarese EP, Cavallone F, et al. Risk of statin-induced hypertransaminasemia: a systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc Innov Qual Out 2019;1:131–40.
[6] Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111–88.
[7] Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45.
[8] Garcia-Cortes M, Lucena ML, Andrade RJ, et al. Is the Naranjo probability scale accurate enough to ascertain causality in drug-induced hepatotoxicity? Ann Pharmacother 2004;38:1540–1.
[9] Belowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins—mechanisms and consequences. Curr Drug Saf 2009;4:209–28.
[10] Russo MW, Hoofnagle JH, Gu J, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology 2014;60:679–86.
[11] Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005;41:690–5.
[12] Meurer L, Cohen SM. Drug-induced liver injury from statins. Clin Liver Dis 2020;24:107–19.
[13] European Association for the Study of the LiverEASL clinical practice guidelines: drug-induced liver injury. Journal of Hepatology 2019;70:1222–61.
[14] Cabrera-Abreu JC, Green A. Gamma-glutamyltransferase: value of its measurement in paediatrics. Ann Clin Biochem 2002;39:22–9.
[15] Mason JE, Starke RD, Van Kirk JE. Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Prev Cardiol 2010;13:36–41.
[16] Yang X, Salminen WF, Schnackenberg LK. Current and emerging biomarkers of hepatotoxicity. Curr Biomark Find 2012;43:61.
[17] Remick SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcome in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011;378:1356–67.
[18] Ramappa V, Aithal GP. Hepatotoxicity related to antituberculosis drugs: mechanisms and management. J Clin Exp Hepatol 2013;3:37–49.
[19] Giordano C, Rivas J, Zervos X. An update on treatment of drug induced liver injury. Am J Gastroenterol 2014;2:72–9.
[20] Cho AR, Kwon YJ, Lim HJ, et al. Oxidative balance score and serum (glutamyltranspeptidase level among Korean adults: a nationwide population-based study. Eur J Nutr 2018;57:1237–44.
[21] Shimizu Y, Kawashiri SY, Kiyoura K, et al. Gamma-glutamyl transpeptidase (iGTP): has an ambivalent association with hypertension and atherosclerosis among elderly Japanese men: a cross-sectional study. Environ Health Prev Med 2019;24:69–75.
[22] Dujovne CA. Side effects of statins: hepatitis versus “transaminitis”: myositis versus “CPKitis”. Am J Cardiol 2002;89:1411–3.
[23] Baker WL, Datta R. Pitavastatin: a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia. Adv Ther 2011;28:13–27.